San Diego-based Cardium Therapeutics has announced that its common stock will be trading on the OTCQB Marketplace under the ticker symbol CRXM effective Friday.
The move to the OTCQB Marketplace does not change Cardium's reporting obligations under applicable laws.
Cardium expects to continue to file its quarterly reports on the form 10-Q, annual reports on form 10-K and current reports on form 8-K.
OTC Markets Group Inc. operates open, transparent and connected financial marketplaces for investors to trade almost 10,000 equity and debt securities through the broker of their choice.
Cardium is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of an interventional cardiology, angiogenic gene therapy product candidate for the treatment for cardiac microvascular insufficiency due to advancing coronary artery disease.